Finn
LEGN Biotechnology · Cell therapy · Oncology · Mid cap · Thesis updated November 15, 2026

Record margins meet growth reality checks and new leadership

01 Running thesis

A strong drug navigating a slower rollout

Legend's bull case rests on CARVYKTI functioning as a sustainably profitable commercial juggernaut. That thesis gained ground in the third quarter of 2026 when gross margins crushed expectations by reaching 58 percent. New clinical guidelines now explicitly prefer CAR-T therapy over bispecific options at the first relapse. The in vivo pipeline also provided a major boost, with the LB2501 program showing a 100 percent complete response rate at dose level 2.

The bear case centers on slowing commercial momentum. Management recently cautioned that consensus 2027 revenue estimates sit at the high end of their scenarios. Community referral behavior is proving harder to change than expected, which is slowing early-line share growth in the United States. International launches are also facing delays.

Further pipeline and competitive questions remain. LB2501 showed an odd drop in efficacy at dose level 3, dropping to a 60 percent response rate. Meanwhile, competitor anito-cel faces a regulatory decision in late 2025, which will test Legend's hold on community hospitals.

Nov 2026→Third quarter 2026 earnings showed a massive gross margin beat at 58 percent. However, management warned that 2027 revenue estimates are likely too high due to slower early-line adoption.
Aug 2026▲Second quarter earnings marked a major milestone with $63 million in adjusted net income. However, the unexpected departure of CEO Ying Huang added execution uncertainty.
May 2026→First quarter results showed strong CARVYKTI demand with 52 percent year-over-year growth, though gross margin temporarily fell to 41 percent due to expansion costs.
Mar 2026▲CARVYKTI became profitable in 2025, and management said it expected company-wide profitability in 2026 on an adjusted basis.
Nov 2025▲Legend said CARVYKTI was no longer supply constrained and that there was no longer a patient waitlist.
Aug 2025▲Second quarter 2025 sales reached $439 million, and the FDA removed REMS requirements for approved BCMA and CD19 autologous CAR-T therapies.
May 2025▲First quarter 2025 showed faster production and stronger ex-U.S. growth, with CARVYKTI net trade sales of $369 million.
02 Business model

One partner, one main product

Legend makes money mainly through its Janssen collaboration for CARVYKTI. Outside China, the companies share pre-tax profits and losses equally. In Greater China, Legend keeps or bears 70 percent of pre-tax profits or losses. Janssen books sales in most markets, while Legend records its share as collaboration revenue.

The financial profile reached a turning point in mid-2026, achieving sustained adjusted net income profitability. A major driver is the outpatient strategy, as treating patients outside the hospital drives volume and community adoption. Outpatient care now makes up roughly 60 percent of the mix.

While outpatient care initially pressured margins, the company proved it could offset those costs with manufacturing efficiencies. The result was a dramatic jump in gross margin to 58 percent in the third quarter of 2026, up from the low 50s.

03 Product portfolio

CARVYKTI first, pipeline later

Growth engine

CARVYKTI

CARVYKTI is Legend's core approved therapy for multiple myeloma, commercialized globally with Janssen. It generated $710 million in global net trade sales in the third quarter of 2026.

Option

CARTITUDE-5 and CARTITUDE-6

These trials push CARVYKTI into earlier myeloma treatment settings, aiming to widen the patient pool.

Option

LB2501

An in vivo CD19/CD20 program for non-Hodgkin lymphoma. It recently showed a 100 percent complete response rate at dose level 2, though efficacy dropped at dose level 3.

Option

LB2505

An in vivo BCMA-targeted therapy. It is entering a clinical study in China subject to the collaboration with Janssen.

Option

LB2102

Legend licensed this DLL3-focused CAR-T program for small cell lung cancer to Novartis. Early data showed a 28.6 percent objective response rate.

04 Business segments

Revenue is highly concentrated

Collaboration revenue92%growing fast
License and other revenue8%declining

The mix is based on fiscal 2025 revenue in Legend's Form 20-F. Collaboration revenue tied to CARVYKTI made up almost all sales.

05 Risk factors

What could break the thesis

Early-line adoption stalls

High impact · High odds

Management warned that 2027 consensus estimates are likely too high due to slower early-line adoption in the United States and delayed international launches. Changing community referral behavior takes time.

We watchWatch second and third line apheresis volume and international launch updates.

Anito-cel pressures the market

Medium impact · Medium odds

Arcellx and Gilead's anito-cel faces an FDA decision in late 2025. A clean approval and strong launch could challenge CARVYKTI's position in community oncology networks.

We watchWatch the anito-cel decision outcome, label language, and first launch trends.

In vivo dose response issues

Medium impact · Medium odds

The LB2501 program showed an unexpected efficacy drop at dose level 3 compared to dose level 2. This raises questions about the therapeutic window and optimal dosing.

We watchWatch for data updates from the U.S. clinical trials for LB2501 to clarify the dose-response curve.

Leadership transition

Medium impact · Medium odds

Legend recently transitioned to a new permanent CEO, Ingrid Zhang. A change in leadership during a critical commercial scaling phase always introduces execution risk.

We watchWatch for changes in commercial strategy or further executive departures.
06 Quick answers

In one breath

What is Legend Biotech best known for?

Legend is best known for CARVYKTI, a BCMA-targeted CAR-T therapy for multiple myeloma. It is the company's first and only approved product.

How does Legend Biotech make money?

Most revenue comes from the Janssen collaboration for CARVYKTI. The two companies share profits and losses, and Legend books its share as collaboration revenue.

Is Legend Biotech profitable?

Yes, the company achieved sustained adjusted net income profitability in mid-2026. Gross margins also improved to 58 percent in the third quarter of 2026.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 15, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Legend Biotech Q3 2026 earnings transcript
  2. Legend Biotech Q2 2026 earnings transcript
  3. Legend Biotech Q1 2026 earnings transcript
  4. Legend Biotech 2025 Form 20-F
08 Explore the industry

Comparable Biotechnology companies

Companies near Legend Biotech Corporation in Finn's Biotechnology industry ranking.

Get started with Finn today